- Home
- SD vs IVA Comparison
SD vs IVA Comparison
Compare SD & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SD
- IVA
- Stock Information
- Founded
- SD 2006
- IVA 2011
- Country
- SD United States
- IVA France
- Employees
- SD N/A
- IVA N/A
- Industry
- SD Oil & Gas Production
- IVA Biotechnology: Pharmaceutical Preparations
- Sector
- SD Energy
- IVA Health Care
- Exchange
- SD Nasdaq
- IVA Nasdaq
- Market Cap
- SD 380.8M
- IVA 359.6M
- IPO Year
- SD 2007
- IVA 2020
- Fundamental
- Price
- SD $11.93
- IVA $3.29
- Analyst Decision
- SD
- IVA Strong Buy
- Analyst Count
- SD 0
- IVA 4
- Target Price
- SD N/A
- IVA $10.50
- AVG Volume (30 Days)
- SD 402.6K
- IVA 27.3K
- Earning Date
- SD 08-06-2025
- IVA 03-26-2025
- Dividend Yield
- SD 3.69%
- IVA N/A
- EPS Growth
- SD 33.83
- IVA N/A
- EPS
- SD 1.74
- IVA N/A
- Revenue
- SD $137,611,000.00
- IVA $14,591,573.00
- Revenue This Year
- SD $37.50
- IVA $15.38
- Revenue Next Year
- SD $5.17
- IVA $24.22
- P/E Ratio
- SD $6.84
- IVA N/A
- Revenue Growth
- SD 1.35
- IVA N/A
- 52 Week Low
- SD $8.81
- IVA $1.53
- 52 Week High
- SD $14.04
- IVA $4.05
- Technical
- Relative Strength Index (RSI)
- SD 76.46
- IVA 45.22
- Support Level
- SD $10.24
- IVA $3.25
- Resistance Level
- SD $12.64
- IVA $3.57
- Average True Range (ATR)
- SD 0.32
- IVA 0.27
- MACD
- SD 0.16
- IVA -0.02
- Stochastic Oscillator
- SD 78.81
- IVA 22.64
About SD SandRidge Energy Inc.
SandRidge Energy Inc is a United States-based oil and natural gas company. It is engaged in the exploration, development, and production of crude oil, natural gas, and Natural gas liquids. Business activities of the group include Exploration and Production, Drilling and Oil Field Services, and Midstream Gas Services. Its primary areas of operation are the Mid-Continent in Oklahoma and Kansas.
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.